PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 27, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report initial preclinical data from its HLA Independent TCR (HiT) targeting mesothelin, being co-developed with Astellas, during a poster presentation at the American Society for Cell and Gene Therapy (ASGCT) meeting. Abstracts were published online today, and data will be updated during the conference.

Read more:
Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *